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Abstract 
Background: The limited health care resources cannot meet all the demands of the society. Thus, decision makers 
have to choose feasible interventions and reject the others. We aimed to collect and summarize the results of all cost 
utility analysis studies that were conducted in Iran and develop a Quality Adjusted Life Year (QALY) league table.
Methods: A systematic mapping review was conducted to identify all cost utility analysis studies done in Iran and 
then map them in a table. PubMed, Embase, Cochrane library, Web of Science, as well as Iranian databases like Iran 
Medex, SID, Magiran, and Barakat Knowledge Network System were all searched for articles published from the 
inception of the databases to January 2020. Additionally, Cost per QALY or Incremental Cost Utility Ratio (ICUR) were 
collected from all studies. The Joanna Briggs checklist was used to assess quality appraisal.
Results: In total, 51 cost-utility studies were included in the final analysis, out of which 14 studies were on cancer, 
six studies on coronary heart diseases. Two studies, each on hemophilia, multiple sclerosis and rheumatoid arthritis. 
The rest were on various other diseases. Markov model was the commonest one which has been applied to in 45% 
of the reviewed studies. Discount rates ranged from zero to 7.2%. The cost per QALY ranged from $ 0.144 in radiogra-
phy costs for patients with some orthopedic problems to $ 4,551,521 for immune tolerance induction (ITI) therapy in 
hemophilia patients. High heterogeneity was revealed; therefore, it would be biased to rank interventions based on 
reported cost per QALY or ICUR.
Conclusions: However, it is instructive and informative to collect all economic evaluation studies and summarize 
them in a table. The information on the table would in turn be used to redirect resources for efficient allocation. in 
general, it was revealed that preventive programs are cost effective interventions from different perspectives in Iran.
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Introduction
The limited healthcare resources cannot meet all the 
demands of the society [1] so, decision makers will have 
to choose feasible interventions and reject the oth-
ers [2]. Thus, health systems should prioritize and use 
their limited resources efficiently. Economic evaluation 
studies is the best tool that aids priority setting and effi-
cient resource allocation in the health sector [3, 4]. Many 
countries have adapted health technology assessment 
systems for evaluation of health interventions where  in, 
technology and, economic evaluation, lies at the heart 
of any health technology assessment (HTA) [1, 3]. Cost 
effectiveness (CE) and cost utility (CU) are the main 
methods used frequently for economic evaluations in 
healthcare sector [4]. However, merely economic evalu-
ation studies cannot fully guide policy-makers to a wide 
range of programs that might be a wise investment. To 
overcome this problem, cost-effectiveness threshold 
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analysis has been developed to identify the level of cost 
per unit of outcome below which an intervention might 
be described as cost-effective [4]. In this regard, league-
tables are a great instrument option for policy-makers to 
determine threshold values to help them make the best 
use of resources but, this necessitates a comprehensible 
league table approach in which a list of ICURs are inter-
preted in the context of specific costs and cost-effective-
ness of competing interventions [7]. League tables rank 
health strategies, programs and interventions in terms 
of cost-effectiveness [5] for numerous diseases [6]. The 
intervention choices on the league table has the interven-
tion with the lowest ICUR or cost per QALY placed at 
the top – and then moves down the list, to interventions 
with sequentially higher ratios, until the budget is used 
up [6–8]. They are valuable tools for prioritizing health 
expenses, especially for national health resources [9, 10]. 
It has been used as a policy tool by high [9], middle and 
low-income countries [5]. League tables are frequently 
used and they have been used for public health by WHO 
in the World Health Report since 2000 [11, 12]. A few 
regional league tables are available for some diseases. For 
example, there are tables for 60 different interventions in 
Africa [6]. The league tables are available in other coun-
tries as well [13]. Results from one of the most important 
studies has provided more than 3600 ICERs for more 
than 2000 health programs and strategies [6].
In Iran’s health system, the systematic use of economic 
evaluation started only few years ago but it has been 
expanding gradually. A league table related to public 
health interventions has not been developed in Iran to 
date. The main purpose of this paper was to assemble all 
cost utility studies systematically and then summarize the 
findings of cost utility analysis studies conducted in Iran 
and thereby, develop a QALY league table for the country. 
In doing so, decision makers would be able to distinguish 
and choose the best cost-effective interventions.
Methods
In this study we aimed to gather all cost-utility studies 
based in Iran and summarize them in a table. PRISMA, 
the methodological guidance for reporting systematic 
reviews, was used in this study [14]. The study protocol 
was registered (R.H) in the international prospective reg-
ister of systematic reviews database (PROSPERO). The 
registration number is CRD42019123313.
Literature search
PubMed, Embase, Cochrane library, Web of Science 
databases as well as Iranian databases like Iran Medex, 
SID, Magiran, and Barakat Knowledge Network System 
were searched (R.H and B.R) for articles published from 
the start to January 2020. This review further searched 
the grey literature, implying documents that are often not 
well represented in indexing databases and usually have 
not been peer reviewed. National Institute for Health 
Research (NIHR), Google, Google Scholar and ministry 
of health webpage were reviewed for grey literature (R.H 
and B.R). We performed iterative reviews of reference 
lists attached to all papers selected for inclusion (R.H). 
The search process had no time nor language restric-
tions. The key words including cost utility, cost effec-
tiveness, health technology assessment, HTA, economic 
evaluation, and QALY Iran were identified from our 
searching of respective literature on economic evaluation 
and health technology assessment studies, and then we 
conducted a search of extracted key words in aforemen-
tioned electronic bibliographic databases.
The complete search strategy in the PubMed data-
base was as follows: cost utility [title/abstract] OR 
cost effectiveness[title/abstract] OR health technology 
assessment[title/abstract] OR HTA [title/abstract] OR 
economic evaluation[title/abstract] OR cost per QALY 
[title/abstract] AND Iran [title/abstract].
The same search strategy was adapted for other inter-
national databases using Boolean operators like OR as 
well as AND.
Eligibility criteria
All cost utility studies reporting cost per QALY or ICUR 
and which were published till January 2020 conducted 
in Iran were eligible for inclusion in this review. On the 
contrary, all letter to editor, conference papers, review 
articles, cost-effectiveness, cost minimization, and cost 
consequences studies, and studies with low standards 
were excluded. Besides, all cost utility studies not done in 
Iran were omitted.
Selection of articles
After removing duplicates, the titles and abstract, the 
papers were screened to eliminate irrelevant papers. All 
the steps were performed by two authors independently 
(R.H and B.R). Discrepancies between the reviewers were 
resolved by discussion or consultation with a third author 
(A.A). Then, the full text of the remaining papers was 
reviewed by the two reviewers separately (R.H and B.R) 
Persisting discrepancies were resolved by third author 
(A.A). All studies reported whether cost per QALY or 
ICUR in Iran were included. All low-quality studies 
(scored less than 6) appeared not to match our inclusion 
criteria and were excluded.
Synthesis
Detailed information was extracted from each included 
study using a pre-structured data extraction form by two 
authors (M.S and N.A), separately. Any discrepancies 
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between them were resolved through discussion; other-
wise, they were resolved by the third author (R.H). Data 
on publication year, type of intervention (drug, screen-
ing, technology, surgery, vaccine, follow-up), year costs, 
sensitivity analysis (one way, two way, probabilistic sen-
sitivity analysis and so on), perspectives adapted (soci-
ety, health system, health insurance organization and so 
forth), discount rate, outcomes (ICUR or cost per QALY) 
and their recommendation were extracted. To standard-
ize the results of studies conducted in different years, 
costs were deflated using the formula below:
n and r are year and inflation rate respectively.
In case an article did not report the year costs, year 
of the paper publication was considered as a base for 
cost adjustment. Moreover, in case an article used Rial 
for calculation, we converted Rial to USD to reduce 
heterogeneity.
Quality assessment
The quality of the eligible studies were determined by 
two independent investigators (M.S and N.A), accord-
ing to the Joana Briggs Institute (JBI) quality assessment 
checklist [15]. The quality appraisal results were checked 
by a third reviewer (R.H). The JBI tool consists of the fol-
lowing 11 appraisal items: (1) well-defined question, (2) 
description of alternatives, (3) relevant costs and out-
comes, (4) effectiveness, (5) outcome and cost measured 
accurately, (6) cost and outcome valued credibly, (7) 
adjusting cost and outcome for different timing, (8) incre-
mental analysis, (9) sensitivity analysis, (10) including all 
concerns, and (11) generalizability. Each item was scored 
as 1 if the study met a criterion, and all the scores were 
summed up to reach a total score, which ranged from 0 
(lowest quality possible) to 11 (highest quality possible). 
The studies were categorized into three types: the studies 
that scored 10 and 11 were considered as excellent qual-
ity studies (1), the studies that scored eight and nine as 
good quality studies (2) the studies that scored seven and 
six were considered as medium quality studies (3).
Results
In total, our initial search yielded 2619 papers; out 
of which, 808 articles were duplicate and they were 
removed. Then, titles and abstracts of the remaining 
papers were reviewed, 1678 of which were excluded and 
133 articles were selected. Full text of 133 articles were 
reviewed and 51 cost utility analysis studies were found 
eligible for inclusion in the final analysis (Fig. 1).
Since there was heterogeneity in the study’s results 
and methods, for instance, in terms of year of costing, 
Future value = Present value × (1+ r)n
and study perspective (viewpoint), the results of them 
cannot be combined or synthesized. however, QALY 
was the most common outcome in all included stud-
ies. Out of the 51 studies, 13 studies were based on 
different cancer-related interventions (e.g. screening, 
chemotherapy and other interventions), followed by 
seven studies on different programs for heart diseases, 
six studies were carried out on orthopedic interven-
tions, four studies were performed on multiple sclerosis 
interventions, two studies were conducted on different 
strategies of hepatitis disease. Table  1 shows studies 
and diseases.
Societal perspective (n = 19), health system (n = 10), 
and payer (n = 6) were the most common perspectives 
taken. Health insurance organization was considered in 
four studies. Provider, third party, ministry of health, 
and government in which each has been adapted as the 
viewpoint in two studies separately. Three studies did 
not state a perspective.
Most articles used Markov model (n = 23), followed 
by Decision Tree (n = 14) and two studies used both 
Markov and Decision Tree models. A quarter of the 
studies did not use any modeling (n = 12).
In 29 studies, discounting has been used. Discount 
rate for cost ranged from 0 to 7.2%. The discount rates 
were 3%, 5%, 7.2%, and 6% in thirteen, eight, four and 
two studies, respectively. After, performing sensitivity 
analysis, the results of two studies were reported with 
discount rates of zero, 3%, and 7.2%. and 20% in stud-
ies which used discounting for outcomes. The discount 
rates for outcomes were 3%, 5%, 6% and 7.2% in seven-
teen, six, two and four studies, respectively. Two stud-
ies used different discount rates of zero, 3% and 7/2% to 
perform the sensitivity analysis.
The majority of studies undertook a sensitivity analy-
sis (n = 47). Some papers used several techniques, but 
Probabilistic analysis (n = 16) was the predominant 
technique, followed by one-way sensitivity analysis 
(n = 15). Sensitivity analysis was reported in two stud-
ies, but the kind of which has not been mentioned.
Result of ICUR and cost per QALY for intervention:
Multiple measures have been used for evaluating out-
come data, including incremental cost, incremental 
QALY, ICUR, and QALY. Various methods of costing, 
modeling, discount rate, and perspectives had been 
used in the selected studies. Hence, there was high het-
erogeneity among variables making it difficult to rank 
interventions based on cost per QALY or ICUR. So, 
we report cost per QALY or ICUR for all interventions 
from different perspectives and then summarized all 
pivotal information in appendix 1 and 2.
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Cancer
five out of twelve studies were performed on breast can-
cer. Mammography in the first round was cost effec-
tive in 53% of cases from the health system perspective 
in Iranian women aged 40–70 years based on modeling 
but it was not cost effective in the second and the third 
rounds. Cost per QALY ranged from 15.75 to 621 USD 
[16]. Adjuvant chemotherapy plus trastuzumab (Cost 
per QALY = 4,756 USD) was not a cost-effective option 
for treating patients with HER2-positive early breast 
cancer versus adjuvant chemotherapy alone (Cost per 
QALY = 1,115 USD) from Iranian health system per-
spective [17]. and intensive follow-up model was not 
cost-effective versus standard follow-up for breast cancer 
from payer perspective with cost per QALY of 178,792 
USD and 381,070 USD respectively [18]. Doxorubicin 
and Cyclophosphamide (AC) with cost per QALY of 
11,554 USD was considered as a cost-effective option 
for the treatment of women with advanced breast can-
cer who were younger than 65 years old versus Gemcit-
abine and Paclitaxel (PG) with cost per QALY of 16,415 
USD from society perspective [19]. 5-fluorouracil, doxo-
rubicin, cyclophosphamide (FAC) was a cost effective 
treatment in women less than 75 years old suffering from 
breast cancer with node-positive versus Docetaxel with 
doxorubicin and cyclophosphamide (TAC) from third-
party perspective [20]. Cost per QALY for FAC and TAC 
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Fig. 1 Flowchart of study and inclusion in studies
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Table 1 The main characteristics of the studies included in the present review
Refs. Year Disease Perspective Quality 
appraisal
[22] 2011 Colon cancer Health Insurance Organization 1
[25] 2019 Gastric cancer Society 1
[18] 2014 Breast cancer Payer 1
[20] 2008 Breast cancer Third party 2
[71] 2012 Colorectal cancer Health care system 1
[19] 2013 Breast cancer Society 2
[17] 2010 Breast cancer Health care system 1
[72] 2013 Lymphoma Society 2
[16] 2012 Breast cancer Health system 1
[23] 2008 Lung cancer Health system 1
[21] 2013 Cervical cancer Government 2
[24] 2017 Lung cancer Health system 1
[73] 2013 Cervical cancer Health provider 1
[30] 2000–2005 Cardiac valve dysfunction No 3
[28] 2010 Coronary heart disease Society 1
[74] 2013 Stroke No 3
[29] 2015 Acute ischemic stroke Third party payer 1
[26] 2015 Myocardial infraction Payer 1
[27] 2014 Myocardial infraction Payer 1
[31] 2019 venous thromboembolism prophylaxis Payer 1
[44] 2014 Chronic Hepatitis C virus Payer 1
[43] 2014 Chronic Hepatitis B Society 1
[32] 2012 Orthopedic condition Ministry of Health 1
[33] 2015 Chronic low back pain Society 2
[33] 2018 chronic low back pain Society 2
[34] 2014 Osteoporosis Health system 1
[38] 2017 Osteoporosis Health Insurance Organization 1
[36] 2019 Severe Postmenopausal Osteoporosis Health System 1
[46] 2011 Multiple sclerosis Health care 1
[45] 2012 Multiple sclerosis Society 1
[47] 2019 Relapsing remitting multiple sclerosis Society 1
2019 Relapsing remitting multiple sclerosis Society 1
[49] 2012 B-thalassemia Society 1
[50] 2018 Thalassemia Society 1
[40] 2015 Hypothyroidism Society 2
[41] 2010 Galactosemia Society 2
[39] 2010 Phenylketonuria Society 2
[42] 2010 Congenital abnormalities Society 2
[35] 2013 Refractory rheumatoid arthritis Health service governor 1
[37] 2014 Rheumatoid arthritis Payer 1
[53] 2014 Depression disorder Health system 2
[45] 2014 Helicobacter pylori infection Provider 2
[59] 2019 Dental disease Health system 1
[57] 2019 Renal Disease Society 1
[60] 2019 Streptococcus pharyngitis Society 2
[55] 2019 Chronic Kidney Disease Health Insurance Organization 1
[58] 2014 Ulcerative coitus No 1
[56] 2019 Febrile seizure Society 1
[52] 2016 HIV Government 2
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Quadrivalent HPV vaccine is not a cost-effective option 
for cervical cancer screening in girls at the age of 15 
from government perspective in Iran. Moreover, cost per 
QALY for different strategies of cervical screening ranged 
from $0.5750 (no screening) to $7.866 (pap smear start-
ing at the age of 21 and repeat every three years) from 
health providers perspective. It is recommended for 
women in Iran to start pap smear at the age of 35 and 
repeat it every 5 or 10 years [21].
The most cost-effective options for colorectal and colon 
cancer are colonoscopy screening every 10 years starting 
at the age of 40 and fecal immunochemical test, or colo-
noscopy every 10 years respectively in the target popula-
tion from health care system perspective. Cost per QALY 
ranged from 67.3 USD (no screening) to139.1 USD (colo-
noscopy) [22].
Pet scan and IEV regimen (ifosfamide, epirubicin and 
etoposide) were cost effective alternatives in the treat-
ment of non-small cell lung carcinoma from health 
system perspective and patients with lymphoma from 
society perspective, respectively [23].
Screening of Smokers aged 55–74 for lung cancer ver-
sus no screening is a cost-effective option from health 
system perspective [24].
It is suggested that oncologists use epirubicin, oxalipl-
atin, and capecitabine (EOX) drug regimen compared to 
docetaxel, cisplatin, and fluorouracil (DCF) for the treat-
ment of patients with gastric cancer. EOX is a cost-effec-
tive drug from society’s perspective [25].
Coronary artery disease
Aspirin is a cost-effective option in men with a 10-year 
CVD risk of 15% from payer perspective[ [26]] and sim-
vastatin 10 mg is a cost-effective intervention in CVD-
healthy men aged 45 with a 10-year CVD risk of 15% for 
the prevention of myocardial infarction from payer per-
spective [27].
Coronary bypass surgery (CBAG) in patients with 
multi-vessel coronary artery disease [28] and, tissue plas-
minogen activator in patients with ischemic stroke [29] 
are cost effective interventions from society and third-
party perspective, respectively. Moreover, homograft 
valve in patients that underwent homograft and mechan-
ical heart valve replacement surgery is a cost effective 
intervention [30].
Enoxaparin for inpatients treatment of venous throm-
boembolism prophylaxis with moderate to high risk is 
not a cost-effective option in comparison to heparin from 
perspective of payer in Iran [31].
Orthopedic disease
EOS imaging technique is not cost-effective in routine 
practice from ministry of health perspective [32]. Elec-
troacupuncture is more cost-effective than nonsteroidal 
anti-inflammatory drugs for the treatment of chronic low 
back pain from society perspective [33]. In another study, 
it is alleged that electroacupuncture is a more cost-effec-
tive intervention that NSAIDs in treatment of patients 
with chronic low back pain from perspective of society 
[33]. For osteoporosis, teriparatide is not a cost-effective 
intervention compared to alendronate and risedronate 
from health system perspective in the treatment of post-
menopausal Iranian women aged 60 years and above [34]. 
Rituximab versus disease-modifying anti rheumatoid 
drugs (DMARDs) is not a cost-effective intervention for 
the treatment of patients with refractory rheumatoid 
arthritis from health service perspective [35]. Teripara-
tide also is a cost-effective option versus no treatment in 
treatment of women with Severe Postmenopausal Osteo-
porosis (PMO) from health system perspective [36].
Moreover, Tocilizumab plus methotrexate compared 
with infliximab plus methotrexate is not a cost-effective 
option for Rheumatoid Arthritis Patients from payer per-
spective [37].
Dual energy absorptiometry (DXA) & osteoporosis 
self- assessment tool (OST) is more cost-effective pro-
gram than DXA in people over 55 years for Osteoporosis 
from health insurance organization perspective [38].
Congenital disease
Screening for PKU versus no screening is beneficial to 
society and patients and ICUR is $33,860 [39]. The ICUR 
of screening versus no screening for hypothyroidism 
among infants is $13,413 from society perspective. Thus, 
the screening is not only economically beneficial, but it 
also, prevents mental retardation [40]. Galactosemia 
screening program versus no screening is both cost-
effective and socially acceptable among infants and ICUR 
is $12,000 from society perspective [41]. ICUR of screen-
ing versus no screening for Phenylketonuria, Hypothy-
roidism, Galactosemia and Favism are $3386, $13,078, 
Table 1 (continued)
Refs. Year Disease Perspective Quality 
appraisal
[61] 2018 Short stature Health Insurance Organization 1
[51] 2011 Hemophilia a Ministry of Health 1
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$19,641 and $1088 respectively from social perspective. 
This neonatal screening yields long term benefits [42].
Hepatitis
In chronic hepatitis B, cost per QALY of medications 
ranged from $3474.78 in Tenofovir (TDF) to $10359.24 
in Entecavir (ETV) in patients with HBeAg-negative 
chronic Hepatitis B from society perspective. Thus, TDF 
in patients with HBeAg-negative CHB is a highly cost-
effective strategy [43].
In the treatment of patients with HCV genotype 1, the 
highest cost per QALY was $3826.8 for Ledipasvir and 
Sofosbuvir (LDV + SOF) and the least cost per QALY was 
$635.4 for Pegylated interferon and Ribavirin + Sofosbu-
vir (SOF + PR). The combination of SOF + PR was most 
cost-effective from payer perspective [44].
Multiple sclerosis (MS)
For patients aged 30 years old diagnosed with relaps-
ing multiple sclerosis, the ICUR varies from $3850 to 
$18,050 for different strategies. All brands of interferon 
beta products except Avonex is cost-effective in treat-
ment of patients from societal perspective [45].
In another study, cost per QALY ranged from $2233.78 
(symptom management) to $15529.78 (Avonex) for the 
treatment of patients with relapsing-remitting multiple 
sclerosis from the perspective of Iran’s health care per-
spective [46].
Moreover, alemtuzumab is a dominant intervention 
versus natalizumab in patients with multiple sclerosis 
from society perspective [47] Alemtuzumab and Natali-
zumab resulted in 25,475 and 28,902 dollars per QALY, 
respectively.
Fingolimod and natalizumab resulted in 27,368 and 
7180 dollar per QALY from perspective of society in 
treatment of patients with multiple sclerosis [48]. it is 
suggested that fingolimod is used as the first priority for 
second-line treatment.
Other diseases
B-thalassemia: DFX (deferasirox) is cost-effective com-
pared to deferoxamine infusion for the treatment of iron 
overload in patients with b-thalassemia from the per-
spective of Iran’s society [49]. In another study, it was 
claimed that treating patients with Thalassemia major is 
a cost-effective intervention versus no treatment from 
social viewpoint [50].
Hemophilia A: low dose ITI (immune tolerance induc-
tion) is more cost-effective than other options for the 
treatment of hemophilia patients with inhibitors from 
Iranian ministry of health perspective [51].
Human immunodeficiency virus (HIV): methadone 
maintain treatment (MMT) is cost effective versus no 
MMT among iv drug users referred to the public MMT 
from governmental perspective [52].
Depression disorder: The repetitive transcranial mag-
netic stimulation is a cost-effective intervention versus 
electroconvulsive therapy in the treatment of depressive 
disorders from health system perspective [53].
Helicobacter pylori: It is recommended to avoid car-
bon-13 urea breath method in large scale among Iranian 
adult population with uninvestigated dyspepsia with 
no history of Non-Steroidal Anti-Inflammatory Drugs 
(NSAID) consumption and had no symptoms of other 
diseases from perspective of providers [54].
Chronic Kidney Disease(CKD): screening of CKD ver-
sus no screening in adult patient is a cost effective pro-
gram from health insurance organization perspective 
[55].
For febrile Seizure in children, Phenobarbital and 
topiramate led to 1051 and 2466 dollars per QALY. 
Topiramate in patients with febrile seizure under five 
years of age is a cost-effective strategy from society per-
spective [56].
Renal disease: ]It is recommended that kidney trans-
plantation is the best intervention compared to hemo-
dialysis and peritoneal dialysis in patients with end stage 
renal disease from perspective of society [57].
Ulcerative coitus: conventional treatment is not a cost-
effective option versus Infliximab in patients with moder-
ate to severe ulcerative coitus [58].
Dental disease: varnish fluoride therapy versus no var-
nish fluoride therapy in students aged 7–12 years is a cost 
effective strategy from perspective of health system [59].
The best strategy in management of pharyngitis is rapid 
test antigen (RTA) from perspective of society. Cost per 
QALY ranged from $3.41 to $4.93 in diagnosis and treat-
ment of pharyngitis [60].
Somatropin is a cost-effective option in comparison 
with no somatropin in treatment of children with short 
stature from health insurance organization perspective 
[61].
Discussion
We found 51 CUA studies that were conducted between 
2000 and 2020 in Iran. With regards to resource scar-
city, it was apparent that the focus of economic evalua-
tions was high on interventions for diseases that impose 
a growing burden on population health. Accordingly, the 
results of the current review highlighted that a large part 
of cost-utility studies concentrates on cancer which is the 
second major health problem in Iran. However, fewer 
studies (n = 6) have been undertaken on cardiovascular 
disease and strokes, which are responsible for roughly 
one-third of the mortality rates in Iran [62]. This finding 
shows that most of the cost-utility analysis studies have 
Page 8 of 11Hashempour et al. Cost Eff Resour Alloc            (2021) 19:3 
concentrated on high burden illness to allocate health 
resources economically.
Economic evaluation should be conducted and inter-
preted within clear and precise theoretical frameworks 
to conduct the research, and to support its interpretation 
[63]. The scope of the costs and benefits is determined by 
the selection of study perspective [64]. The predominant 
viewpoint in the studies analyzed was society (n = 19), 
which ensures addressing costs and benefits attributable 
to patients and society as a whole. There is a consensus 
among economists that the reliable perspective in eco-
nomic evaluation is societal. A societal viewpoint entails 
that all costs and benefits should be included in the 
evaluation as wide as possible, irrespective of who pays 
or receives them [63]. It has been further observed that 
three studies have not stated their perspectives. Based 
on the review of articles, about 63% of them adopted 
narrow viewpoints on impeding generalizability and not 
including overall long-term implications in their analy-
ses. Yet, some studies specified that perspectives failed 
to estimate the associated consequences concerning the 
adopted viewpoint.
Discounting refers to the translation of values drawn 
from a certain time horizon in the future to the pre-
sent value that aims to make costs and benefits com-
parable throughout different years [65]. There is some 
controversy over the rate that should be employed to 
discount benefits and costs. Most of the countries have 
recommended reporting results with benefit and costs 
discounted at a range of 3–5 percent to ensure some 
consistency in the findings of economic evaluations. The 
current review found that majority of studies in the Ira-
nian setting used the discount rate varied between 0 and 
7.2% and 3% was the mode, which is consistent with the 
WHO’s guidelines on discounting [66]. Nevertheless, 
a few studies ignored or did not report discounting. In 
addition, it must be mentioned that there is no need to 
perform discount rate for short-run studies Since ICUR 
results are very sensitive to differences in discount rates, 
using a higher discount rate gives somewhat little weight 
to costs and benefits in the remote future, hence it can 
notably affect the decisions made.
Sensitivity analysis is performed to discover the effect 
of uncertainty on findings by changes in values of inputs 
and assumptions [67]. Researchers should perform a sen-
sitivity analysis to assess the robustness of results. One-
way sensitivity analysis was the most common technique 
that has been done owing to the uncertainty of a single 
component (e.g., by changing discount rate). However, 
for a more favorable validation of findings, probabilistic 
as well as multi-dimensional sensitivity analyses are sug-
gested to not only assess the robustness of results but also 
to facilitate generalizability of findings to other settings.
From the review of articles, we found that Markov 
models (n = 23) were the most common analytic tech-
niques followed by the decision tree models (n = 14). 
Markov models are useful when a decision problem 
involves a risk that is continuous over time, when the 
timing of events is important, and when important events 
may happen more than once. Representing such clinical 
settings with conventional decision trees is difficult and 
may require simplifying unrealistic assumptions. Markov 
models assume that a patient is always in one of the finite 
numbers of discrete health states, called Markov states. 
All events are represented as transitions from one state to 
another [68]. The evaluation of the studies in this review 
reflects a paucity of information useful for making deci-
sions about the allocation of resources for healthcare 
interventions. It is actually, concerning that over 6 per-
cent of Iranian GDP is being spent on the health system, 
with insufficient economic evidence.
In CUA studies, multiple domain scores from Health-
Related Quality of Life (HRQoL) instruments are trans-
lated into a single summary utility score. By doing so, 
QALY estimates, and thus cost-utility ratios, as well as 
ICUR can be calculated [69]. Cost utility analyses adapt 
QALY measurement which is comparable and general-
izable across various interventions as an instrument for 
comparing their value for money. Thus, ICUR is defined 
as the ratio of the difference in cost between two alter-
natives to the difference in effectiveness (QALY) between 
the same two alternatives. Each of CUAs included in this 
study has weighed the cost and effectiveness of a compet-
ing intervention against another one to give the decision-
maker a precise quantitative understanding of their likely 
effectiveness. Based on findings in the present study, 
league table for Iranian CUA studies begins with $ 0.144 
per-QALY ratio for radiography with the minimum ICUR 
in patients with any orthopedic problems from perspec-
tive of ministry of health and ends with $ 1,675,535 per 
QALY for immune tolerance induction (ITI) therapy with 
the maximum ICUR in treatment of hemophilia patients 
with inhibitors from perspective of health ministry. The 
major shortcoming of league tables for Iranian CUA 
studies may be the omission of much of the information 
that decision-makers might want to take into account 
when choosing alternatives. For instance, in recent years, 
few studies have been conducted on economic evaluation 
of interventions concerning cardiovascular disease while 
those diseases represented nearly %9 of disease burden, 
but 11% of the CUA studies in our review were related to 
them. However, there appears to be an imbalance existing 
between disease burden and studies.
It was revealed that screening programs related to all 
diseases were cost effective interventions except two 
studies [16, 21]. In one study [16] it was cost effective to 
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use mammography in women aged 40–70 in 53% of tri-
als but it was not cost effective to use it in second and 
third round. In the other study [21], Quadrivalent HPV 
vaccine was not cost effective. The reason for that may be 
attributed to ignoring some possible benefits. The other 
screening strategies were cost effective from different 
perspectives in Iran due to high effectiveness or low cost. 
So, decision makers should allocate resources to screen-
ing programs because they would use lower cost and 
produce more QALY. On the other hand, in treatment 
strategies, due to low effectiveness or high expenses, 
most of the options were not cost effective. In summary, 
we addressed the quality of CUA studies in Iran and sug-
gest that the adherence to technical criteria needs to 
improve and methodological flaws in published work 
should be removed to ensure that economic evaluations 
do not mislead policy-makers and serve as tools of advo-
cacy to witness which interventions are most cost- effec-
tiveness (efficient). It is suggested that decision makers 
develop a webpage like Iranian Registry of Clinical Tri-
als (IRCT) [70] for registration of economic evaluation 
studies, and generate agreed and international guidelines 
of what to do economic evaluations. In addition, obli-
gating researchers to follow the determined guidelines 
before conducting the economic evaluation studies might 
increase homogeneity and comparability among the 
studies.
Conclusions
League table serves as an approach which can help deci-
sion-makers to distil policy recommendations when 
confronting with imperfect information during the pro-
cess of resource allocation in a rational way. Although 
economic evaluations have been conducted alongside 
higher heterogeneity and no ranking was performed, it is 
instructive and informative to collect all cost utility stud-
ies and summarize them in a table. Moreover, there was 
a limited number of economic evaluation studies related 
to different disease to make better decision for various 
strategies for every disease. As the findings illustrate, in 
general, screening programs were found cost effective 
interventions from different perspectives in Iran due to 
high effectiveness or low cost. Hence, decision makers 
are suggested to allocate resources to screening programs 
because they would use lower financial resources and 
produce more benefits.
Limitations
• High heterogeneity was revealed and sorting was not 
carried out.
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